JP2010536759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536759A5 JP2010536759A5 JP2010521043A JP2010521043A JP2010536759A5 JP 2010536759 A5 JP2010536759 A5 JP 2010536759A5 JP 2010521043 A JP2010521043 A JP 2010521043A JP 2010521043 A JP2010521043 A JP 2010521043A JP 2010536759 A5 JP2010536759 A5 JP 2010536759A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- avpal variant
- use according
- stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6612507P | 2007-08-17 | 2007-08-17 | |
| US61/066,125 | 2007-08-17 | ||
| PCT/US2008/009765 WO2009025760A2 (en) | 2007-08-17 | 2008-08-15 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536759A JP2010536759A (ja) | 2010-12-02 |
| JP2010536759A5 true JP2010536759A5 (enExample) | 2011-10-06 |
| JP5584120B2 JP5584120B2 (ja) | 2014-09-03 |
Family
ID=40363135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521043A Active JP5584120B2 (ja) | 2007-08-17 | 2008-08-15 | 原核生物フェニルアラニンアンモニアリアーゼの組成物、及び、その組成物を用いる癌の治療方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7537923B2 (enExample) |
| EP (1) | EP2175875B1 (enExample) |
| JP (1) | JP5584120B2 (enExample) |
| CN (1) | CN101803492B (enExample) |
| AR (2) | AR067972A1 (enExample) |
| AU (1) | AU2008289549B2 (enExample) |
| BR (2) | BR122018072594B8 (enExample) |
| CA (1) | CA2687028C (enExample) |
| CL (1) | CL2008002390A1 (enExample) |
| CY (1) | CY1118222T1 (enExample) |
| DK (1) | DK2175875T3 (enExample) |
| ES (1) | ES2602618T3 (enExample) |
| HR (1) | HRP20161474T1 (enExample) |
| HU (1) | HUE029510T4 (enExample) |
| LT (1) | LT2175875T (enExample) |
| MX (1) | MX2009012261A (enExample) |
| PE (1) | PE20090605A1 (enExample) |
| PL (1) | PL2175875T3 (enExample) |
| PT (1) | PT2175875T (enExample) |
| RU (2) | RU2553343C2 (enExample) |
| SI (1) | SI2175875T1 (enExample) |
| TW (1) | TWI418787B (enExample) |
| WO (1) | WO2009025760A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| US8796206B2 (en) * | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| WO2011078667A2 (en) | 2009-12-22 | 2011-06-30 | Dsm Ip Assets B.V. | Method of finding a biocatalyst having ammonia lyase activity |
| EP4062928A3 (en) | 2010-02-04 | 2022-11-30 | BioMarin Pharmaceutical Inc. | Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia |
| WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| EP3222288A1 (en) * | 2012-07-27 | 2017-09-27 | University of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| PL2986722T3 (pl) | 2013-04-18 | 2019-10-31 | Codexis Inc | Skonstruowane polipeptydy amoniakoliazy fenyloalaniny |
| BR112016011195A2 (pt) | 2013-11-18 | 2017-09-19 | Rubius Therapeutics Inc | Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico |
| CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| EP3145536B1 (en) | 2014-04-16 | 2021-10-27 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3137103B1 (en) | 2014-04-29 | 2021-10-20 | Bio-Cancer Treatment International Ltd. | Methods and compositions for modulating the immune system with arginase i |
| EP3169791A1 (en) | 2014-07-14 | 2017-05-24 | Danmarks Tekniske Universitet | Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity |
| CA2970638A1 (en) | 2014-12-22 | 2016-06-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| JP6994018B2 (ja) | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
| IT201600086488A1 (it) * | 2016-08-22 | 2018-02-22 | St Microelectronics Srl | Dispositivo a semiconduttore e corrispondente procedimento |
| AU2018217495B2 (en) * | 2017-02-13 | 2021-03-04 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| KR20210008501A (ko) | 2018-05-09 | 2021-01-22 | 바이오마린 파머수티컬 인크. | 페닐케톤뇨증을 치료하는 방법 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| EP3807409A4 (en) | 2018-06-12 | 2022-08-03 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| MY207075A (en) | 2018-12-20 | 2025-01-28 | Codexis Inc | Human alpha-galactosidase variants |
| CN113727733B (zh) | 2019-02-14 | 2023-01-24 | 索姆创新生物技术公司 | 用于治疗苯丙酮尿症的氨苯蝶啶或诺拉曲塞 |
| JP2022543611A (ja) * | 2019-08-07 | 2022-10-13 | ラクテン・メディカル，インコーポレイテッド | セツキシマブ－ｉｒ７００コンジュゲート組成物 |
| BR112022003705A2 (pt) | 2019-08-30 | 2022-05-24 | Codexis Inc | Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso |
| MX2022007399A (es) | 2019-12-20 | 2022-09-19 | Codexis Inc | Variantes de alfa-glucosidasa ácida diseñadas. |
| EP4103711A4 (en) | 2020-02-04 | 2024-02-28 | Codexis, Inc. | Engineered leucine decarboxylases |
| TW202144575A (zh) | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
| JP2023539634A (ja) | 2020-08-28 | 2023-09-15 | コデクシス， インコーポレイテッド | 操作されたアミラーゼバリアント |
| AU2021334371A1 (en) | 2020-08-28 | 2023-03-09 | Codexis, Inc. | Engineered protease variants |
| WO2022245924A1 (en) | 2021-05-19 | 2022-11-24 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects |
| AU2022279241A1 (en) | 2021-05-21 | 2023-11-30 | Syntis Bio, Inc. | Engineered methionine gamma lyase variants |
| JP2024540358A (ja) | 2021-11-01 | 2024-10-31 | シンティス バイオ，インコーポレイティド | 工学操作ロイシン脱炭酸酵素 |
| CN115873837A (zh) * | 2022-11-18 | 2023-03-31 | 安徽盈科生物科技有限公司 | 高表达的新型的苯丙氨酸解氨酶 |
| CN118931888A (zh) * | 2023-05-09 | 2024-11-12 | 重庆派金生物科技有限公司 | 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐 |
| GB202307239D0 (en) | 2023-05-15 | 2023-06-28 | Evox Therapeutics Ltd | Gene therapies for Phenylketonuria |
| WO2025106759A1 (en) | 2023-11-17 | 2025-05-22 | Biomarin Pharmaceutical Inc. | Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) * | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| WO1994013817A1 (en) | 1992-12-04 | 1994-06-23 | Me Medical Enzymes Ag | Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| US5212939A (en) * | 1991-12-04 | 1993-05-25 | Pratt Jr John M | Marine mooring swivel fitting |
| JP2930723B2 (ja) * | 1992-11-19 | 1999-08-03 | アンティキャンサー インコーポレーテド | 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用 |
| DK75593D0 (enExample) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| KR0164757B1 (ko) * | 1995-06-13 | 1999-01-15 | 김광호 | 공조장치의 살균집진장치와 그 방법 |
| ATE455171T1 (de) * | 1995-09-21 | 2010-01-15 | Genentech Inc | Varianten des menschlichen wachstumshormons |
| CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) * | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US6451986B1 (en) * | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) * | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6686164B1 (en) * | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| CA2328614C (en) * | 1999-02-12 | 2012-06-26 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| EP1280924A2 (en) | 2000-04-14 | 2003-02-05 | University of South Carolina Research Foundation | Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| US6967097B2 (en) * | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| US6939941B2 (en) * | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
| JP4722396B2 (ja) | 2002-02-26 | 2011-07-13 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 遺伝要素の組換え方法 |
| JP2006516095A (ja) | 2002-11-14 | 2006-06-22 | ザ スクリップス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形 |
| AU2005286763A1 (en) | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical, Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| EP1869174B1 (en) * | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| DE102006032167B4 (de) | 2006-07-12 | 2014-11-27 | Evonik Degussa Gmbh | Verfahren zur Herstellung von Triallylisocyanurat (TAIC) |
| WO2008069958A2 (en) | 2006-12-01 | 2008-06-12 | The Salk Institute For Biological Studies | Substrate switched ammonia lyases and mutases |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
-
2008
- 2008-04-22 US US12/107,736 patent/US7537923B2/en active Active
- 2008-04-22 US US12/107,731 patent/US7560263B2/en active Active
- 2008-08-14 CL CL2008002390A patent/CL2008002390A1/es unknown
- 2008-08-15 RU RU2012134838/15A patent/RU2553343C2/ru active
- 2008-08-15 CN CN200880016488.XA patent/CN101803492B/zh active Active
- 2008-08-15 PT PT87953576T patent/PT2175875T/pt unknown
- 2008-08-15 BR BR122018072594A patent/BR122018072594B8/pt active IP Right Grant
- 2008-08-15 PL PL08795357T patent/PL2175875T3/pl unknown
- 2008-08-15 WO PCT/US2008/009765 patent/WO2009025760A2/en not_active Ceased
- 2008-08-15 HU HUE08795357A patent/HUE029510T4/en unknown
- 2008-08-15 PE PE2008001395A patent/PE20090605A1/es active IP Right Grant
- 2008-08-15 RU RU2009141987/15A patent/RU2009141987A/ru not_active Application Discontinuation
- 2008-08-15 DK DK08795357.6T patent/DK2175875T3/en active
- 2008-08-15 JP JP2010521043A patent/JP5584120B2/ja active Active
- 2008-08-15 TW TW097131325A patent/TWI418787B/zh active
- 2008-08-15 AU AU2008289549A patent/AU2008289549B2/en active Active
- 2008-08-15 ES ES08795357.6T patent/ES2602618T3/es active Active
- 2008-08-15 MX MX2009012261A patent/MX2009012261A/es active IP Right Grant
- 2008-08-15 SI SI200831703A patent/SI2175875T1/sl unknown
- 2008-08-15 AR ARP080103596A patent/AR067972A1/es not_active Application Discontinuation
- 2008-08-15 CA CA2687028A patent/CA2687028C/en active Active
- 2008-08-15 BR BRPI0811589A patent/BRPI0811589B8/pt active IP Right Grant
- 2008-08-15 LT LTEP08795357.6T patent/LT2175875T/lt unknown
- 2008-08-15 HR HRP20161474TT patent/HRP20161474T1/hr unknown
- 2008-08-15 EP EP08795357.6A patent/EP2175875B1/en active Active
-
2009
- 2009-04-09 US US12/421,557 patent/US7790433B2/en active Active
-
2010
- 2010-07-09 US US12/833,911 patent/US20100278802A1/en not_active Abandoned
-
2016
- 2016-11-10 CY CY20161101163T patent/CY1118222T1/el unknown
-
2019
- 2019-01-24 AR ARP190100158A patent/AR117389A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6966678B2 (ja) | Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害 | |
| CN102459647B (zh) | 与干扰素-α应答有关的遗传标记 | |
| Kouretova et al. | Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication | |
| RU2009141987A (ru) | Композиции прокариотической фенилаланин-аммиак-лиазы и способы лечения рака с использованием таких композиций | |
| Kopp et al. | Chemoenzymatic design of acidic lipopeptide hybrids: new insights into the structure− activity relationship of daptomycin and A54145 | |
| Sidhu et al. | Unsatisfactory quality of E. coli asparaginase biogenerics in India: implications for clinical outcomes in acute lymphoblastic leukaemia | |
| JP6928324B1 (ja) | 滑膜細胞増殖抑制剤、関節腔注入剤、及び食品組成物 | |
| JP2006506942A5 (enExample) | ||
| JP2009527498A (ja) | 癌におけるｃａＰＣＮＡ相互作用のペプチドによる抑制 | |
| KR101746160B1 (ko) | 결핵균 독소-항독소 체계를 표적으로 하는 항생 펩타이드 및 이의 용도 | |
| CN107001419A (zh) | 神经变性障碍 | |
| WO2021212056A2 (en) | Engineered interleukin-22 polypeptides and uses thereof | |
| Gámez et al. | Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria | |
| CN106232810A (zh) | 新的治疗 | |
| Tan et al. | De Novo Discovery of a Noncovalent Cell-Penetrating Bicyclic Peptide Inhibitor Targeting SARS-CoV‑2 Main Protease | |
| CN114272244B (zh) | 恩曲替尼或其盐的新用途 | |
| KR20200012894A (ko) | 펩타이드 및 항바이러스제로서의 이의 용도 | |
| Park et al. | Selective inhibition of human inducible nitric oxide synthase by S‐alkyl‐L‐isothiocitrulline‐containing dipeptides | |
| ES2648487T3 (es) | Antagonistas de factor de crecimiento endotelial vascular y métodos para su uso | |
| US20240228543A1 (en) | Cyclic peptide inhibitors of usp22 | |
| TW201722414A (zh) | Ev71感染的組合治療 | |
| US9670250B2 (en) | Alpha-helical peptidomimetic inhibitors and methods using same | |
| WO2025137361A1 (en) | Compositions and methods for targeting insulin receptor isoform a (ir-a) | |
| WO2006054757A1 (ja) | カスパーゼ阻害剤 | |
| HK40102025A (en) | Inhibition of cytokine-induced sh2 protein in nk cells |